Global High-throughput Screening Market Growth, Trends, and Forecast Report 2019-2024 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “High-throughput
Screening Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.

The high-throughput screening market is expected to register a CAGR of
7.8%, during the forecast period

North America dominates the market, owing to large spending on
pharmaceutical R&D and high adoption of high-throughput screening
technology in drug discovery.

The high-throughput screening (HTS) centers in the public domain have
increased significantly over the past decade, ranging in size, from
modestly-equipped academic screening centers to well-endowed molecular
libraries probe centers network (MLPCN). These centers facilitate a
comprehensive approach to probe discovery in academia, and utilize,
both, standard and innovative assay technologies for executing primary
and secondary screening campaigns.

One of the significant advantages of these centers was knowledge sharing
among scientists, researchers, etc. In European countries,
EU-open-screen, European counterpart of US NIH initiative, is also
working to get open access to all European organizations involved in
chemical biology. Additionally, the association of HTS centers is also
emerging, which is aimed at sharing valuable information about the
compound or target, or the whole process. The open access provides a
better platform for knowledge sharing, and can help optimize the entire
process, which may drive the demand for HTS technology among end users.

HTS systems allow tens of thousands or even hundreds of thousands of
compounds to be evaluated in a single day. As the throughput increases,
the amount of data for each experiment increases, and scientists analyze
and derive results from large amounts of data. Due to the sheer number
of samples being processed and the massive volume of data being
produced, the need for extensive automation techniques arises, to
streamline the operations. However, automation requires massive
investments for the establishment of machinery and supporting
architecture, which are roadblocks for small- and moderate-size research
institutes. Thus, the high costs associated with automation techniques
can limit the market expansion.

Scope of the Report

The high-throughput screening market has been segmented by technology,
applications, products and services, end user, and geography. By
technology, the market is divided into an ultra-high-throughput
screening, cell-based assays, lab-on-a-chip, and label-free technology.
By application, the market has been subdivided into target
identification, primary screening, and toxicology. By products and
services, the market has been segmented into instruments, reagents and
kits, and services. By end user, the market has been segmented into
pharmaceutical and biotechnology firms, academia and research
institutes, and contract research organizations.

Key Market Trends

Pharmaceutical and Biotechnology Firms Represent the Largest End Users
of High-throughput Screening Modalities.

In order to gain sustainable competitive advantage, most of the large
and small biotechnology and pharmaceutical companies are focusing on the
development of novel molecules for the treatment of several chronic
conditions. The need for rapid and precise screening of several target
molecules, during drug discovery and development phases, has led to the
adoption of automated high-throughput screening techniques to screen
massive chemical and biomarker libraries generated during the research
processes. Since an automated HTS system can test 10,000 to 100,000
target compounds per day, and uHTS can test more than 100,000 compounds
per day, their adoption for drug discovery and development process has
resulted in the market expansion.

North America is Expected to Dominate the Market

North America dominates the global high-throughput screening market,
owing to the high adoption rate of HTS in the United States. The growth
of the US high-throughput screening market can be attributed to the
significant advances in combinatorial chemistry and the field of
genomics. In addition, huge investments by the pharmaceutical industry,
for HTS technologies, in terms of automation, miniaturization, and assay
methodology, have further helped in the growth of the market.
Furthermore, the end users of this market have witnessed increasing
numbers of leads, clinical candidates, and marketed drugs arising from
high-throughput screening.

Competitive Landscape

The high-throughput screening market is highly competitive and consists
of several major players. Most of the major players enjoy a global
presence, and are facing intense competition in emerging economies. The
emerging countries are becoming hotspots of significant competition, due
to a rapidly expanding market size, fueled by growing investments in R&D
and the recent trend of contract research outsourcing.

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Market Drivers

4.2.1 Open Access to High-throughput Screening Laboratories

4.2.2 Technological Advancements in HTS

4.2.3 Increasing Usage in Universities and Research Centers

4.3 Market Restraints

4.3.1 High Capital Investment

4.3.2 Need for Extensive Automation Techniques

4.4 Porter’s Five Forces Analysis

5 MARKET SEGMENTATION

5.1 By Technology

5.1.1 Ultra-high-throughput Screening

5.1.2 Cell-based Assays

5.1.3 Lab-on-a-chip

5.1.4 Label-free Technology

5.2 By Applications

5.2.1 Target Identification

5.2.2 Primary Screening

5.2.3 Toxicology

5.3 By Products and Services

5.3.1 Instruments

5.3.2 Reagents and Kits

5.3.3 Services

5.4 By End Users

5.4.1 Pharmaceutical and Biotechnology Firms

5.4.2 Academia and Research Institutes

5.4.3 Contract Research Organizations

5.5 Geography

6 COMPETITIVE LANDSCAPE

6.1 Company Profiles

6.1.1 Agilent Technologies Inc.

6.1.2 Axxam SpA

6.1.3 Beckman Coulter Inc.

6.1.4 Bio-Rad Laboratories Inc.

6.1.5 Danaher Corporation

6.1.6 GE Healthcare

6.1.7 Merck KGaA

6.1.8 PerkinElmer Inc.

6.1.9 Tecan Group Ltd

6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

For more information about this report visit https://www.researchandmarkets.com/r/byfn22

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Drug
Discovery